AdvertisementSupported byBy Chad BrayLONDON — The Danish biotechnology company Bavarian Nordic said on Wednesday that it could receive up to $975 million under a licensing agreement with Bristol-Myers Squibb for Prostvac, a treatment for advanced prostate cancer that is in clinical trials.Under the agreement, Bavarian Nordic will receive a $60 million upfront payment and could receive as much as $975 million, based on certain milestones.In a news release, Bristol-Myers Squibb said it would have an exclusive option to license and commercialize Prostvac, which uses the body’s immune system to fight prostate cancer.Bristol-Myers Squibb said it was exploring a clinical trial of combining Prostvac with Yervoy, a drug it is developing to treat skin cancer that has spread.Shares of Bavarian Nordic jumped 27 percent to 268.5 Danish kroner, or about $40.30, in early trading in Copenhagen on Wednesday.Advertisement